New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

NURTEC ODT (rimegepant) tablets. FDA-Approved. To treat Migraine

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email to discuss.

NURTEC ODT (rimegepant) orally is a prescription medicine. NURTEC ODT (rimegepant) FDA Approved is used to treat migraine.
NURTEC ODT is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults.
DOSAGE FORMS & STRENGTHS: NURTEC ODT orally disintegrating tablets: 75 mg
Manufactured By: Biohaven Pharmaceuticals Inc.
Prescribing Information URL: Click Here

South Delhi Pharma facilitate the supply of “NURTEC ODT (rimegepant) FDA Approved” medication. Supplied under Named Patient Program to all locations in India and other part of countries. Anti-Cancer drugs is available upon request after fulfilling the legal requirement (if applicable). To get best price share your mobile number and email ID.


Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:

Query Form


Rimegepant, sold under the brand name Nurtec ODT, is a medication for the treatment of an acute migraine with or without aura in adults. It is not used prophylactically.

Taken by mouth to dissolve on or under the tongue, rimegepant takes effect within an hour and can provide relief from migraine headache for up to 48 hours. It is not a narcotic and has no addictive potential; thus it is not designated as a controlled substance.[medical citation needed] It works by blocking CGRP receptors.

Approved for use in the United States in February 2020, rimegepant is produced and marketed by Biohaven Pharmaceuticals, based in New Haven, Connecticut.

Related Products